SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Cytokinetics, Inc. (CYTK)

CYTK RSS Feed
Add CYTK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/16/2017 5:44:54 PM - Followers: 66 - Board type: Free - Posts Today: 0


 

 

Cytokinetics is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery, development and commercialization of therapeutics. Similarly, it is more and more uncommon for a biopharmaceutical company to leverage their expertise in one area, in our case the cytoskeleton  and the biology of muscle function, to tackle the pursuit of new treatments for multiple disease areas. However, the most important distinguishing feature of Cytokinetics is instead found in our commitment to innovation that has translated our focus on the cytoskeleton into a Research and Development pipeline of multiple, first-in-class compounds. All of the programs we are pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. The reason is simple. Innovative therapeutics are much more likely to bring substantial benefits to patients. That is our goal.

Based in South San Francisco, we employ approximately 81 employees. Working collaboratively in a company that embodies uncommon values, Cytokinetics' devoted and passionate personnel, are all focused on advancing novel therapeutics to dramatically improve the lives of patients. With purpose and passion, we have committed to make an important impact on serious medical illnesses. We are pleased that you are visiting our website to learn more about Cytokinetics.

Company Links:

Investor's Relations

SEC Filings

Cytokenetics Team

Pipeline

Omecamtiv Mecarbil Clinical Trial (PH 2) (October 2013)


CK-2017357 Clinical Trial (PH 2) (September 2012) 




Third Party Links:

NASDAQ 

Market Watch

Barchart









 




 >

 

 .

SureTrader
Interactive Brokers Advertisement
CYTK
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CYTK News: Cytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017 11/13/2017 02:10:00 PM
CYTK News: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the American Heart Association Scientific Session... 11/06/2017 04:20:20 PM
CYTK News: Current Report Filing (8-k) 11/06/2017 06:04:19 AM
CYTK News: Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) 11/03/2017 05:26:59 PM
CYTK News: Securities Registration: Employee Benefit Plan (s-8) 11/03/2017 05:07:57 PM
PostSubject
#1468   H2R what is the likelihood of the phase Sugarshaker 11/16/17 05:44:53 PM
#1467   CYTK is expecting ALS Ph III in a H2R 11/13/17 03:37:05 PM
#1466   Wow glad I didn’t buy too many shares? Sugarshaker 11/07/17 09:56:12 AM
#1465   $75M stock sales deal with Cantor H2R 11/06/17 03:14:40 PM
#1464   New 8-k out today H2R 10/31/17 04:44:55 PM
#1463   Great Long term Stock Potential Even if Tirasemtiv H2R 10/30/17 03:03:52 PM
#1462   A nice post CC market action for CYTK today. H2R 10/27/17 11:31:09 AM
#1461   Some Notable Items (easier with the transcript :) H2R 10/27/17 10:22:19 AM
#1460   Thanks H2R. Sugarshaker 10/27/17 07:33:36 AM
#1459   And also getting ready for the U.S. market, H2R 10/26/17 08:09:03 PM
#1458   They are still targeting the Dec. 8th meeting, H2R 10/26/17 05:05:34 PM
#1457   CC today AH H2R 10/26/17 03:25:18 PM
#1456   New SA article on CYTK H2R 10/26/17 03:18:42 PM
#1455   The only thing I see is the earnings H2R 10/25/17 02:50:02 PM
#1454   Where are you H2R any idea what’s Happening? Sugarshaker 10/25/17 11:59:31 AM
#1453   Has something leaked out? Sugarshaker 10/19/17 12:12:14 PM
#1452   Oct 26th: Conf Call H2R 10/17/17 01:09:11 PM
#1451   October trial updates and some completion, Sugarshaker 10/16/17 05:36:44 PM
#1450   Reminder of the Ph III ALS study: H2R 10/13/17 03:50:35 PM
#1449   Wow NWBO has been killed this year that’s Sugarshaker 10/13/17 12:14:25 PM
#1448   Hi Sugarshaker, H2R 10/13/17 08:00:57 AM
#1447   Thanks again H2R are you by yourself on Sugarshaker 10/12/17 12:15:26 PM
#1446   Sorry to hear that Sugarshaker,that's one terrible disease. H2R 10/12/17 10:06:07 AM
#1445   Thanks H2R I know it’s extremely hard to Sugarshaker 10/11/17 05:41:46 PM
#1444   Thanks H2R I know it’s extremely hard to Sugarshaker 10/11/17 05:41:45 PM
#1443   From an SA article today: H2R 10/11/17 01:16:33 PM
#1442   What are the chances of good results from Sugarshaker 10/10/17 10:23:33 AM
#1441   Top line results will likely be released in November. H2R 09/29/17 02:13:15 PM
#1440   Update from SoS on the stock he covers, H2R 09/29/17 02:12:24 PM
#1439   $10M milestone reached :) H2R 09/19/17 02:01:01 PM
#1438   New presentation at the 21st Annual Heart Failure H2R 09/11/17 06:24:49 PM
#1437   ..And up again, no news, well, except the H2R 08/28/17 06:58:18 PM
#1436   New SoS Analysis: Bullish.Financial Standing. H2R 08/07/17 03:49:08 PM
#1435   And back down to $13+. What a strange H2R 08/04/17 05:17:11 PM
#1434   ... and now down over 7%! I'm not H2R 08/03/17 11:14:59 AM
#1433   Expected VITALITY-ALS Phase 3: Q4 2017 tracking! H2R 08/02/17 09:17:07 PM
#1432   The financials look good! H2R 08/02/17 09:15:36 PM
#1431   ... followed by a solid day, up %4.95 H2R 08/02/17 09:00:28 PM
#1430   POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF H2R 08/02/17 08:33:01 AM
#1429   New Corporate Pres at http://ir.cytokinetics.com/phoenix.zhtml?c=142156&p=irol-irhome H2R 05/23/17 03:22:57 PM
#1428   Orphan Designation for CYTK Treatment of spinal muscular atrophy H2R 05/12/17 12:08:03 PM
#1427   Thinking a bit more about the offering, CYTK H2R 05/09/17 06:25:51 PM
#1426   CYTK Prices 5.36M Offering at $14.25/Sh H2R 05/09/17 02:24:11 PM
#1425   SoS article after Edaravone FDA approval H2R 05/08/17 01:33:30 PM
#1424   The competition: edaravone approved (Mitsubishi Tanabe Pharma Corp. - H2R 05/05/17 05:52:21 PM
#1423   Cytokinetics and the ALS Association Renew Partnership to H2R 05/04/17 12:51:53 PM
#1422   VITALITY-ALS patients continue on Open Label Extension H2R 04/28/17 11:28:43 AM
#1421   Calendar Update: On Track for ALS Q4 2017 H2R 04/27/17 04:10:03 PM
#1420   From $13.45 to $16.90 in 5 days! H2R 04/26/17 09:55:40 PM
#1419   And the SA author's reply to a comment H2R 04/26/17 09:52:44 PM
PostSubject